229 related articles for article (PubMed ID: 30910588)
1. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.
Roundhill EA; Jabri S; Burchill SA
Cancer Lett; 2019 Jul; 453():142-157. PubMed ID: 30910588
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
3. Establishment of new multidrug-resistant human osteosarcoma cell lines.
Oda Y; Matsumoto Y; Harimaya K; Iwamoto Y; Tsuneyoshi M
Oncol Rep; 2000; 7(4):859-66. PubMed ID: 10854558
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
6. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
[TBL] [Abstract][Full Text] [Related]
7. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
8. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes.
La Sala D; Macaluso M; Trimarchi C; Giordano A; Cinti C
Oncogene; 2003 Jun; 22(23):3518-29. PubMed ID: 12789260
[TBL] [Abstract][Full Text] [Related]
9. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
10. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Gonçalves C; Martins-Neves SR; Paiva-Oliveira D; Oliveira VE; Fontes-Ribeiro C; Gomes CM
Life Sci; 2015 Jun; 130():47-56. PubMed ID: 25818183
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line.
Martins-Neves SR; Lopes ÁO; do Carmo A; Paiva AA; Simões PC; Abrunhosa AJ; Gomes CM
BMC Cancer; 2012 Apr; 12():139. PubMed ID: 22475227
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.
Mealey KL; Barhoumi R; Rogers K; Kochevar DT
Cancer Lett; 1998 Apr; 126(2):187-92. PubMed ID: 9585065
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of LIMK1 promotes migration ability of multidrug-resistant osteosarcoma cells.
Zhang H; Wang Y; Xing F; Wang J; Wang Y; Wang H; Yang Y; Gao Z
Oncol Res; 2011; 19(10-11):501-9. PubMed ID: 22715593
[TBL] [Abstract][Full Text] [Related]
14. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Takeshita H; Gebhardt MC; Springfield DS; Kusuzaki K; Mankin HJ
J Bone Joint Surg Am; 1996 Mar; 78(3):366-75. PubMed ID: 8613443
[TBL] [Abstract][Full Text] [Related]
15. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
16. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.
Souès S; Laval F; Charcosset JY
Br J Cancer; 1995 Mar; 71(3):489-97. PubMed ID: 7880729
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
20. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
